SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0000897069-22-000045
Filing Date
2022-01-31
Accepted
2022-01-31 17:00:54
Documents
2

Document Format Files

Seq Description Document Type Size
1 cmw361.htm SC 13D/A 179790
3 image0.jpg GRAPHIC 13283
  Complete submission text file 0000897069-22-000045.txt   200066
Mailing Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142
Business Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142 (857) 999-0075
KalVista Pharmaceuticals, Inc. (Subject) CIK: 0001348911 (see all company filings)

IRS No.: 200915291 | State of Incorp.: DE | Fiscal Year End: 0430
Type: SC 13D/A | Act: 34 | File No.: 005-88797 | Film No.: 22574807
SIC: 2834 Pharmaceutical Preparations

Mailing Address TWO UNION SQUARE, 601 UNION ST. SUITE 3200 SEATTLE WA 98101
Business Address TWO UNION SQUARE, 601 UNION ST. SUITE 3200 SEATTLE WA 98101 650-325-5156
Frazier Life Sciences Public Fund, L.P. (Filed by) CIK: 0001863769 (see all company filings)

IRS No.: 862999645 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A